Related Experiment Video
Updated: Aug 13, 2025
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer
Rajesh Pradhan1, Anuradha Dey2, Rajeev Taliyan1
1Department of Pharmacy, Birla Institute of Technology and Science, Pilani 333031, India.
Abstract:
Triple-negative breast cancer (TNBC) is a life-threatening form of breast cancer which has been found to account for 15% of all the subtypes of breast cancer. Currently available treatments are significantly less effective in TNBC management because of several factors such as poor bioavailability, low specificity, multidrug resistance, poor cellular uptake, and unwanted side effects being the major ones. As a rapidly growing field, nano-therapeutics offers promising alternatives for breast cancer treatment. This platform provides a suitable pathway for crossing biological barriers and allowing sustained systemic circulation time and an improved pharmacokinetic profile of the drug. Apart from this, it also provides an optimized target-specific drug delivery system and improves drug accumulation in tumor cells. This review provides insights into the molecular mechanisms associated with the pathogenesis of TNBC, along with summarizing the conventional therapy and recent advances of different nano-carriers for the management of TNBC.
Insights
Triple-negative breast cancer (TNBC) is aggressive, with limited treatment options. Nanotherapeutics offer a promising approach to improve drug delivery and efficacy for TNBC management.
Area of Science:
- Oncology
- Nanomedicine
- Drug Delivery Systems
Background:
- Triple-negative breast cancer (TNBC) accounts for 15% of breast cancer subtypes and presents significant treatment challenges.
- Current TNBC therapies suffer from poor bioavailability, low specificity, multidrug resistance, and adverse side effects.
- Nanotherapeutics are emerging as a promising alternative for enhanced breast cancer treatment.
Purpose of the Study:
- To review the molecular mechanisms underlying TNBC pathogenesis.
- To summarize conventional therapies for TNBC.
- To explore recent advancements in nano-carrier applications for TNBC management.
Main Methods:
- Literature review of TNBC pathogenesis.
- Analysis of conventional TNBC treatment strategies.
- Synthesis of current research on nano-carriers for TNBC therapy.
Main Results:
- Nanotherapeutics facilitate crossing biological barriers, prolong circulation time, and improve pharmacokinetic profiles.
- Nano-carriers enable optimized target-specific drug delivery and enhanced drug accumulation in tumor cells.
- This review consolidates insights into TNBC molecular mechanisms and nano-therapeutic advancements.
Conclusions:
- Nanotherapeutics represent a significant advancement in overcoming the limitations of conventional TNBC treatments.
- Targeted drug delivery via nano-carriers holds potential for improved therapeutic outcomes in TNBC.
- Further research into nano-therapeutics is crucial for developing more effective TNBC management strategies.
